Compare Eli Lilly And Co (LLY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Smith & Nephew plc — how do they compare? Eli Lilly And Co trades at $1,173 (market cap $1.02T), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Eli Lilly And Co is far larger — about 80.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| LLY | SNN | |
|---|---|---|
Market Cap | $1.02T | $12.64B |
Sector | Health | Health |
52-Week High | $1.24K | $38.70 |
52-Week Low | $625.65 | $28.73 |
Enterprise Value | $1.06T | $15.41B |
Dividend Yield | 0.6% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
